Cullinan Oncology LLC (CGEM)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Cullinan Oncology LLC.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 18 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 16.50 $ — 84% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 91.8% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 9
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -3.00 | -3.54 – -1.76 | 18 | 10.8% | 9 |
| 12/31/2027 | -2.53 | -3.73 – -0.34 | 40 | 15.7% | 8 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.71 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.81 | – | 0 | – | – | -37 | -37 |
| 2025: Q1 | -0.82 | – | 0 | – | – | -43 | -43 |
| 2025: Q2 | -1.19 | – | 0 | – | – | -58 | -58 |
| 2025: Q3 | -0.86 | – | 0 | – | – | -37 | -37 |
| 2025: Q4 | -0.86 | – | 0 | – | – | -38 | -38 |
| 2026: Q1 | -0.84 | – | 0 | – | – | -46 | -46 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2015 | 0 | 0 | 0 | – | 0 | -1 | 0 |
| 2016 | 0 | 0 | 0 | – | 0 | -1 | 0 |
| 2018 | 0 | -15 | -14 | -17.74 | -14 | -21 | 35 |
| 2019 | 0 | -22 | -20 | -19.69 | -21 | -41 | 100 |
| 2020 | 19 | -60 | -51 | -1.17 | -30 | 199 | 215 |
| 2021 | 19 | -68 | -65 | -1.47 | -43 | 425 | 437 |
| 2022 | 0 | 145 | 111 | 2.38 | -127 | 535 | 561 |
| 2023 | 0 | -191 | -153 | -3.69 | -134 | 454 | 484 |
| 2024 | 0 | -197 | -167 | -3.11 | -145 | 590 | 622 |
| 2025 | 0 | -242 | -220 | -3.72 | -176 | 409 | 448 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Cullinan Therapeutics, Inc., ein biopharmazeutisches Unternehmen in der klinischen Phase, entwickelt Therapien für Autoimmunerkrankungen und Krebs in den USA.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 109 |
| Headquarters | Cambridge, MA |
| Address | One Main Street, 02142 Cambridge, United States |
| Phone | 617 410 4650 |
| Website | cullinantherapeutics.com |
| IPO Date | 8. Jan 2021 |
| ISIN | US2300311063 |
| Stock Split | 2:1 on 08/31/2009 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Nadim Ahmed M.S. | President, CEO & Director | 1968 |
| Mary Kay Fenton CPA | Chief Financial Officer | 1964 |
| Jeffrey Jones M.B.A., M.D., M.P.H. | Chief Medical Officer | 1971 |
| Patrick A. Baeuerle Ph.D. | Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board | 1958 |
| Jennifer Michaelson Ph.D. | Chief Scientific Officer | 1967 |
| Nicholas Smith | Head of Investor Relations | – |
| Jacquelyn L. Sumer J.D. | Chief Legal Officer, Chief Compliance Officer & Corporate Secretary | 1978 |
| Steve Andre | Chief Human Resources Officer | – |
| Corinne Savill Ph.D. | Chief Business Officer | 1959 |
| Rose Weldon | Senior Vice President of Corporate Affairs | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.